Pfizer Income Statement (2009-2026) | PFE

Income Statement Mar2009 Jun2009 Sep2009 Dec2009 Apr2010 Jul2010 Oct2010 Dec2010 Apr2011 Jul2011 Oct2011 Dec2011 Apr2012 Jul2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Apr2016 Jul2016 Oct2016 Dec2016 Apr2017 Jul2017 Oct2017 Dec2017 Apr2018 Jul2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Apr2021 Jul2021 Oct2021 Dec2021 Apr2022 Jul2022 Oct2022 Dec2022 Apr2023 Jul2023 Oct2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
18.90B24.04B3.42B25.66B27.74B22.64B3.26B3.63B3.49B1.65B3.43B14.88B13.28B0.44B2.11B2.27B2.30B17.56B2.34B
Cost of Revenue (Quarter)
7.00B9.93B9.98B8.65B6.06B4.89B3.24B9.27B7.56B3.38B3.30B5.26B2.85B3.78B4.17B5.27B3.55B
Gross Profit (Quarter)
11.90B14.10B15.68B19.09B16.57B-1.26B0.25B-7.62B-4.13B11.50B9.98B-4.82B-0.73B-1.50B-1.87B12.29B-1.21B
Operating items
Amortization - Intangibles (Quarter)
0.92B0.97B0.83B0.82B0.82B1.10B1.18B1.18B1.27B1.31B1.31B1.31B1.21B1.21B1.22B1.23B1.18B
Research & Development (Quarter)
2.24B2.68B2.30B2.81B2.70B2.50B2.65B2.71B2.81B2.49B2.70B2.60B2.20B2.48B2.55B3.21B2.49B
Selling, General & Administrative (Quarter)
2.92B2.90B2.59B3.05B3.39B3.42B3.50B3.28B4.58B3.50B3.72B3.24B3.03B3.42B3.19B4.16B2.96B
Restructuring Costs (Quarter)
-0.00B0.64B0.19B0.19B0.18B-0.04B0.14B0.15B1.59B0.01B1.10B0.31B0.68B-0.07B0.24B0.77B0.05B
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
5.16B6.22B5.09B6.05B6.26B5.88B6.28B6.15B8.98B6.00B7.52B6.16B5.91B5.82B5.97B8.13B5.50B
Operating Income (Quarter)
6.74B7.88B10.59B13.04B10.31B-7.14B-6.03B-13.77B-13.11B5.50B2.47B-10.98B-6.64B-7.33B-7.84B4.15B-6.71B
EBIT (Quarter)
6.74B7.88B10.59B13.04B10.31B-7.14B-6.03B-13.77B-13.11B5.50B2.47B-10.98B-6.64B-7.33B-7.84B4.15B-6.71B
Non-operating items
Other Non Operating Income (Quarter)
1.34B1.70B-0.35B-0.77B0.06B-0.28B0.07B-0.18B0.16B-0.68B-1.11B-0.24B-0.95B-0.74B-0.52B-4.51B-0.86B
Non Operating Income (Quarter)
1.34B1.70B-0.35B-0.77B0.06B-0.28B0.07B-0.18B0.16B-0.68B-1.11B-0.24B-0.95B-0.74B-0.52B-4.51B-0.86B
Net income details
EBT (Quarter)
6.95B7.84B9.05B11.45B9.00B6.27B2.27B-3.35B-4.13B3.42B-0.10B4.71B2.79B3.04B3.33B-1.64B3.17B
Tax Provisions (Quarter)
1.12B-0.33B1.17B1.57B0.36B0.71B-0.07B-0.96B-0.78B0.29B-0.13B0.23B-0.19B0.14B-0.22B-0.00B0.46B
Profit After Tax (Quarter)
5.83B8.16B0.58B7.86B9.91B8.64B0.23B0.50B0.38B-2.38B0.06B3.13B0.04B4.46B2.97B2.91B3.55B-1.63B2.71B
Income from Non-Controlling Interests (Quarter)
0.03B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.01B0.02B0.01B0.01B0.01B
Income from Continuing Operations (Quarter)
5.83B8.17B7.88B9.88B8.64B5.55B2.34B-2.39B-3.35B3.13B0.03B4.48B2.97B2.90B3.55B-1.64B2.71B
Consolidated Net Income (Quarter)
-0.24B-0.01B-0.01B0.03B-0.02B0.00B-0.00B0.01B-0.03B-0.01B0.02B-0.01B0.03B-0.01B
Income towards Parent Company (Quarter)
-0.24B-0.01B-0.01B0.03B-0.02B0.00B-0.00B0.01B-0.03B-0.01B0.02B-0.01B0.03B-0.01B
Net Income towards Common Stockholders (Quarter)
-0.24B-0.01B-0.01B0.03B-0.02B0.00B-0.00B0.01B-0.03B-0.01B0.02B-0.01B0.03B-0.01B
Additional items
EPS (Basic) (Quarter)
1.041.451.401.771.540.980.41-0.42-0.590.550.010.790.520.510.62-0.290.48
EPS (Weighted Average and Diluted) (Quarter)
1.021.431.371.731.510.970.41-0.42-0.590.550.010.780.520.510.62-0.290.47
Shares Outstanding (Weighted Average) (Quarter)
5.59B5.60B5.60B5.62B5.61B5.61B5.61B5.63B5.65B5.65B5.64B5.66B5.66B5.67B5.66B5.67B5.68B5.68B5.68B5.69B
Shares Outstanding (Diluted Average) (Quarter)
5.67B5.72B5.71B5.76B5.71B5.73B5.73B5.73B5.72B5.65B5.71B5.70B5.70B5.70B5.70B5.71B5.71B5.71B5.71B5.73B
EBITDA (Quarter)
6.74B7.88B10.59B13.04B10.31B-7.14B-6.03B-13.77B-13.11B5.50B2.47B-10.98B-6.64B-7.33B-7.84B4.15B-6.71B
Tax Rate (Quarter)
16.16%-4.18%12.95%13.72%3.96%11.40%-3.13%28.76%18.89%8.56%130.10%4.96%-6.79%4.63%-6.48%0.12%14.54%